Brawn Biotech

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE899B01015
NSEID:
BSEID: 530207
View on BSE

INR

20.05

0.00 (0.00%)

BSENSE

Jun 10, 03:30 PM

BSE+NSE Vol: 860

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beryl Drugs

Brawn Biotech

Vivanza Biosci.

Unjha Formul.

Decipher Labs

Genomic Valley

Ganga Pharma.

Shyama Computro.

Fabino Enter

Saroja Pharma In

Triochem Product

Why is Brawn Biotech Ltd ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -13.45% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.26

Flat results in Mar 26

Risky - Negative EBITDA

The company has recorded a negative EBITDA of Rs. -0.32 cr
Over the past year, while the stock has generated a return of 23.38%, its profits have risen by 152.5% ; the PEG ratio of the company is 0
The stock is trading risky as compared to its average historical valuations

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Brawn Biotech for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Brawn Biotech

23.38%

0.40

58.05%

Sensex

-10.21%

-0.78

13.06%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.45%

EBIT Growth (5y)

3.54%

EBIT to Interest (avg)

-1.26

Debt to EBITDA (avg)

0.23

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

2.97

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.35%

ROCE (avg)

-26.36%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.63

EV to EBIT

-5.83

EV to EBITDA

-5.83

EV to Capital Employed

1.66

EV to Sales

0.34

PEG Ratio

0.04

Dividend Yield

ROCE (Latest)

-25.36%

ROE (Latest)

25.41%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

PAT(Latest six months)

Higher at Rs 0.63 cr

EPS(Q)

Highest at Rs 1.93

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Brawn Biotech

Profit After Tax (PAT) - Quarterly

Highest at Rs 0.58 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 1.93

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)